ADO’s Bus Fleet Renovation and Top Win International’s Investment Plans
ADO announced an investment exceeding 2,000 million pesos in the complete overhaul of its fleet for its Platino and GL services.
The addition of 303 new units marks the beginning of a new era in Mexico’s ground transportation, offering a more comfortable and exclusive travel option for both domestic and international passengers to connect from the country’s center to its south.
This renovation aligns with ADO’s historical vision of placing the passenger at the center, as they did in 1939 by introducing First Class to Mexico.
Fleet Expansion Plan
- ADO intends to incorporate 83 units into the ADO Platino service by 2025.
- ADO plans to add 220 units to the ADO GL service by 2025.
- These units will connect over 50 destinations in the central and southern regions from more than 70 terminals, transporting over 3 million passengers annually between both services.
Top Win International’s DV8 Public Co. Acquisition Plan
Top Win International plans to present a Voluntary Public Offer (OPAM) for the acquisition of up to 11.58% of DV8 Public Co.’s ordinary shares and unexercised warrants, alongside other bitcoin-focused investors.
The offer price is 56 satangs Thai (approximately $0.02) per share and 1 satang per warrant, as reported by Top Win in a recent statement.
The offer is expected to close on August 20.
Mustang Bio’s Stock Surge
Mustang Bio’s stock price soared nearly 174% on Wall Street Monday following the U.S. Food and Drug Administration’s (FDA) granting of Orphan Drug designation to the company for its MB-101, a treatment for diffuse and anaplastic recurrent astrocytoma and glioblastoma.
The designation offers incentives, including tax credits for clinical trial costs post-approval and exemptions from prescription drug user fees, as per the company’s report.
Preclinical data supports a novel combination of MB-101 and MB-108 to optimize clinical outcomes, according to Mustang Bio.
FDA Grants Orphan Drug Designation to Mustang Bio
The FDA awarded Mustang the Orphan Drug designation for MB-108, a treatment for malignant glioma.
Apple to Appeal €500 Million EU Fine
Apple, the American technology giant, plans to appeal a €500 million (approximately $587 million) fine imposed by the European Union for violating the EU’s Digital Markets Act.
The European Commission penalized the Cupertino, California-based company for leveraging its dominant market position to impose restrictions on software developers using its platform, negatively impacting consumers.
“As our appeal will demonstrate, the European Commission is imposing terms that confuse developers and harm users,” stated Apple.
